Extracorporeal life support: The precarious balance of hemostasis

Journal of Thrombosis and Haemostasis

Volumn 13, Issue S1, 2015, Pages S336-S342

  Annich, G M ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Blood coagulation; Blood coagulation tests; Extracorporeal membrane oxygenation; Platelets; Thrombosis

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBIN; HEPARIN;

ACTIVATED COAGULATION TIME; ADSORPTION; ANTIFACTOR XA ASSAY; BIOASSAY; BLOOD CLOTTING; BLOOD CLOTTING TIME; BLOOD EXAMINATION; CELL INTERACTION; COMPLEMENT ALTERNATIVE PATHWAY; CRITICALLY ILL PATIENT; DRUG MONITORING; ENDOTHELIUM CELL; ERYTHROCYTE; EXTRACORPOREAL LIFE SUPPORT; FIBRINOLYSIS; HEMOSTASIS; HUMAN; INTENSIVE CARE; LEUKOCYTE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; THROMBOCYTE; THROMBOELASTOGRAPHY; THROMBOELASTOMETRY; VASCULAR PATENCY; ADVERSE EFFECTS; ANIMAL; BLEEDING; BLOOD; BLOOD CLOTTING TEST; CHEMICALLY INDUCED; CRITICAL ILLNESS; DEVICES; DRUG EFFECTS; EQUIPMENT DESIGN; EXTRACORPOREAL OXYGENATION; MORTALITY; PROCEDURES; RISK ASSESSMENT; RISK FACTOR; THROMBOSIS; TREATMENT OUTCOME;

ANIMALS; ANTICOAGULANTS; BLOOD COAGULATION; BLOOD COAGULATION TESTS; CRITICAL ILLNESS; DRUG MONITORING; EQUIPMENT DESIGN; EXTRACORPOREAL MEMBRANE OXYGENATION; HEMORRHAGE; HUMANS; RISK ASSESSMENT; RISK FACTORS; THROMBOSIS; TREATMENT OUTCOME;

EID: 84931292531     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12963     Document Type: Review

References (30)

1. Annich GM, Cornell T, Massicotte P, Lequier L. Blood biomaterial surface interaction during ECLS. In: Annich G, MacLaren G, Senior eds. ECMO: Extracorporeal Cardiopulmonary Support in Critical Care, 4th edn. Ann Arbor, MI: Extracorporeal Life Support Organization, 2012: 91-102.
2. Hoffman M. A cell-based model of coagulation and the role of factor VIIa. Blood Rev 2003; 17: S1-5.
3. Peek GJ, Firmin RK. The inflammatory and coagulative response to prolonged extracorporeal membrane oxygenation. ASAIO J 1999; 45: 250-63.
4. Urlesberger B, Zobel G, Zenz W, Kuttnig-Haim M, Maurer U, Reiterer F, Riccabona M, Dacar D, Gallistl S, Leschnik B, Muntean W. Activation of the clotting system during extracorporeal membrane oxygenation in term newborn infants. J Pediatr 1996; 129: 264-8.
5. McManus ML, Kevy SV, Bower LK, Hickey PR. Coagulation factor deficiencies during initiation of extracorporeal membrane oxygenation. J Pediatr 1995; 126: 900-4.
6. Woodman RC, Harker LA. Bleeding complications associated with cardiopulmonary bypass. Blood 1990; 76: 1680-97.
7. Gorbet MB, Sefton MV. Biomaterial-associated thrombosis: roles of coagulation factors complement, platelets and leukocytes. Biomaterials 2004; 25: 5681-703.
8. Levy JH, Tanaka KA. Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 2003; 75: S715-20.
9. Fortenberry JD, Bhardwaj V, Niemer P, Cornish JD, Wright JA, Bland L. Neutrophil and cytokine activation with neonatal extracorporeal membrane oxygenation. J Pediatr 1996; 128: 670-8.
10. Barstad RM, Ovrum E, Ringdal MA, Oystese R, Hamers MJ, Veiby OP, Rolfsen T, Stephens RW, Sakariassen KS. Induction of monocyte tissue factor procoagulant activity during coronary artery bypass surgery is reduced with heparin-coated extracorporeal circuit. Br J Haematol 1996; 94: 517-25.
11. Volk HD, Reinke P, Docke WD. Clinical aspects: from systemic inflammation to 'immunoparalysis'. Chem Immunol 2000; 74: 162-77.
12. Hummel M, Docke WD, Friedel N, von Baehr R, Hetzer R, Volk HD. Monitoring of the cellular immune system in patients with biventricular assist devices awaiting cardiac transplantation. Clin Transplant 1994; 8: 59-66.
13. Valhonart H, Swinford RD, Ingelfinger JR, Williams WW, Ryan DP, Tolkoff-Rubin N, Cosimi AB, Pascual M. Rapid activation of the alternative pathway of complement by extracorporeal membrane oxygenation. ASAIO J 1999; 45: 113-4.
14. Vane JR, Anggard EE, Botting RM. Regulatory functions of the vascular endothelium. N Eng J Med 1990; 323: 27-36.
15. Annich G, Adachi I. Anticoagulation for pediatric mechanical circulatory support. Pediatr Crit Care Med 2013; 14: S37-42.
16. Lequier L, Annich GM, Massicotte P. Anticoagulation and bleeding during ECLS. In: Annich G, MacLaren G, Senior eds. ECMO: Extracorporeal Cardiopulmonary Support in Critical Care, 4th edn. Ann Arbor, MI: Extracorporeal Life Support Organization, 2012: 137-50.
17. Lequier L, Annich GM, Al-Ibrahim O, Bembea M, Brodie D, Brogan T, Buckvold S, Chicoine L, Conrad S, Cooper D, Dalton H, Frischer J, Harris B, Mazor R, Paden M, Rintoul N, Ryerson L, Spinella P, Teruya J, Winkler A, et al. ELSO Anticoagulation Guidelines. 2014. 3-9. https://www.elso.org/Portals/0/Files/elsoanticoagulationguideline8-2014.pdf. Accessed 23 February 2015.
18. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990; 86: 385-91.
19. Hattersley PG. Activated coagulation time of whole blood. JAMA 1966; 2: 436-44.
20. Bembea MM, Annich GM, Rycus P, Oldenburg G, Berkowitz I, Pronovost P. Variability in anticoagulation management of patients on extracorporeal membrane oxygenation: an international survey. Pediatr Crit Care Med 2013; 14: e77-84.
21. Palatianos GM, Foroulis CN, Vassili MI, Astras G, Triantafillou K, Papadakis E, Lidoriki AA, Iliopoulou E, Melissari EN. A prospective, double-blind study of the efficacy of the bioline surface-heparinized extracorporeal perfusion circuit. Ann Thorac Surg 2003; 76: 129-35.
22. Marcolin R, Bonbino M, Fumagalli R, Pesenti A. Venovenous ELS with heparin bonded circuits. Int J Artif Organs 1995; 18: 624-6.
23. Tayama E, Hayashida N, Akasu K, Kosuga T, Fukunaga S, Akashi H, Kawara T, Aoyagi S. Biocompatibility of heparin-coated extracorporeal bypass circuits: new heparin bonded bioline system. Artif Organs 2000; 24: 618-23.
24. Annich GM, Meinhardt JP, Mowery KA, Ashton BA, Merz SI, Hirschl RB, Meyerhoff ME, Bartlett RH. Reduced platelet activation and thrombosis in extracorporeal circuits coated with nitric oxide release polymers. Crit Care Med 2000; 28: 915-20.
25. Batchelor MM, Reoma SL, Fleser PS, Nuthakki VK, Callahan RE, Shanley CJ, Politis JK, Elmore J, Merz SI, Meyerhoff ME. More lipophilic dialkyldiamine-based diazeniumdiolates: synthesis, characterization, and application in preparing thromboresistant nitric oxide release polymeric coatings. J Med Chem 2003; 46: 5153-61.
26. Skrzypchak AM, Lafayette NG, Bartlett RH, Zhou Z, Frost MC, Meyerhoff ME, Annich GM. Effect of varying nitric oxide release to prevent platelet consumption and pre- serve platelet function in an in vivo model of extracorporeal circulation. Perfusion 2007; 22: 193-200.
27. Major TC, Brant DO, Burney CP, Amoako KA, Annich GM, Meyerhoff ME, Handa H, Bartlett RH. The hemocompatibility of a nitric oxide generating polymer that catalyzes S-nitrosothiol decomposition in an extracorporeal circulation model. Biomaterials 2011; 32: 5957-69.
28. Amoako KA, Archangeli C, Handa H, Major T, Meyerhoff ME, Annich GM, Bartlett RH. Thromboresistance characterization of extruded nitric oxide-releasing silicone catheters. ASAIO J 2012; 58: 238-46.
29. Ranucci M, Ballotta A, Kandil H, Isgrò G, Carlucci C, Baryshnikova E, Pistuddi V. Bivalirudin-based versus conventional heparin anticoagulation for postcardiotomy extracorporeal membrane oxygenation. Crit Care 2011; 15: R275.
30. Nagle EL, Dager WE, Duby JJ, Roberts AJ, Kenny LE, Murthy MS, Pretzlaff RK. Bivalirudin in pediatric patients maintained on extracorporeal life support. Pediatr Crit Care Med 2013; 14: e182-8.